Action Pharma completes EUR 5 million financing round to advance its lead project AP214

04-Jun-2010 - Denmark

Action Pharma A/S has completed an internal financing round of EUR 5 million which is dedicated to advance the Company’s ongoing phase 2a studies, and the initiation of a phase 2b study, for AP214.

AP214 is being developed for the protection of acute kidney injury in patients undergoing cardiac surgery under cardiopulmonary bypass as its lead indication. Interim phase 2a efficacy and safety data are expected by the end of June 2010.

There following current shareholders of Action Pharma participated in the above financing round: Sunstone Capital, Global Life Science Ventures, SLS Invest and InnovationsKapital.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance